CBT-004 / Cloudbreak Therap - LARVOL DELTA

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula (clinicaltrials.gov) - P2 | N=88 | Completed | Sponsor: Cloudbreak Therapeutics, LLC | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ May 2025 | Trial primary completion date: Aug 2025 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Ophthalmology

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Cloudbreak Therapeutics, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ Oct 2025 | Trial primary completion date: Dec 2023 ➔ Aug 2025

Enrollment open • Trial completion date • Trial primary completion date • Ophthalmology

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Cloudbreak Therapeutics, LLC | Trial primary completion date: Sep 2023 ➔ Dec 2023

Trial primary completion date • Ophthalmology

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Cloudbreak Therapeutics, LLC | Trial completion date: Dec 2022 ➔ Dec 2023 | Initiation date: Mar 2022 ➔ Nov 2022 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Trial completion date • Trial initiation date • Trial primary completion date • Ophthalmology